Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress
April 15, 2021
Our Mission
With our differentiated approach to arming the body’s innate immune systems, we are focused on delivering new treatments beyond the limitations of existing therapies.
Affimed (NASDAQ: AFMD) pioneers immune cell engagement, employing its insights and scientific expertise to harness the body’s innate immune systems in the fight against cancer and other life-threatening diseases. Our proprietary ROCK® (Redirected Optimized Cell Killing) platform allows for the modular design of tetravalent bi- and multi-specific antibodies, including first-in-class innate and adaptive cell engager products.
Our Approach
We are actualizing the next advancement in immuno-oncology (I-O) through our proprietary ROCK® platform, which stands for Redirected Optimized Cell Killing. Our new approach to build ROCK® based innate cell engagers aims to treat a broad range of hematologic and solid tumors by countering tumor immune evasion through activating a patient’s own innate immune system.
Our Pipeline
Our ROCK® platform-designed tetravalent bispecific innate cell engagers are being studied in a number of clinical and preclinical programs. These innate cell engagers are the first to demonstrate a favorable safety profile and promising signs of therapeutic efficacy.
Innate Cell Engagers